Genentech's future after closing cancer immunology group

Plus: ESMO news and roundups 

September 17, 2024 Check out STAT+

Sponsored By

Justin Sullivan/Getty Images STAT+ | Genentech, a biotech with a storied past, confronts new turbulence in the present The closure of the company's cancer immunology group and multiple rounds of layoffs have prompted concern about its future. By Jonathan Wosen STAT+ | After 10 years of game-changing immunotherapies, a cancer conference celebrates — and sees more work to do The ESMO meeting was an opportunity for many to give thanks for what therapies like Keytruda and Opdivo have achieved, and to consider what comes next. By Andrew Joseph STAT+ | Exact Sciences reports initial positive results in colon cancer blood test, but pivot trial still pending The initial results suggest that Exact's test could be an alternative to others on the market, but the findings come from a small study. By Jonathan Wosen Andrew Joseph/STAT STAT+ | AstraZeneca's Imfinzi increases survival rates in bladder cancer in pivotal study  If the trial design doesn't trigger regulatory issues, the results could reshape how muscle-invasive bladder tumors are treated. By Andrew Joseph STAT+ | Incyte's checkpoint inhibitor staves off disease progression in anal cancer trial The immunotherapy could win approval as a treatment for a tumor type that's largely caused by an HPV infection. By Andrew Joseph STAT+ | Pfizer drug shows promise in cancer-related condition that causes weight loss and weakness The company reported at the annual ESMO meeting that an experimental antibody helped cancer patients with a condition known as cachexia. By Andrew Joseph Andrew Joseph/STAT STAT+ | Bristol immunotherapy improves responses in lung cancer, setting up Phase 3 study The study identified which subgroup of lung cancer patients benefitted the most from a combination of Bristol Myers Squibb's immunotherapies. By Andrew Joseph

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Cancer Briefing? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2024, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser